Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102125 · ClinicalTrials.gov registry record · Phase 4
Allograft Dysfunction in Heart Transplant
A Phase 4 study of Heart Transplant Failure and Rejection, sponsored by Paul Kim.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 376
- Enrollment target
- 1
- Study location
NCT03102125: Recruiting Phase 4 study of Heart Transplant Failure and Rejection, sponsored by Paul Kim.
NCT03102125 is a Phase 4 study of Heart Transplant Failure and Rejection that is actively recruiting participants, run by Paul Kim. The registered enrollment target is 376 participants, above the 136-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (176% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03102125, a Phase 4 study of Heart Transplant Failure and Rejection, is actively recruiting participants, sponsored by Paul Kim.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 376 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
Conditions Studied
Interventions
- DRUG Regadenoson
Study Locations (1)
California
- UC San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2025-12-02 |
| Phase | Phase 4 |
What NCT03102125 shows while recruiting
NCT03102125 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, above the 136-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (176% higher).
The record links to 1 condition, with Heart Transplant Failure and Rejection appearing as the primary indexed condition, and to 1 intervention - of which Regadenoson is the first listed.
NCT03102125 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03102125 about?
NCT03102125 is a clinical study titled "Allograft Dysfunction in Heart Transplant". The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
What is the current status of trial NCT03102125?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 376 participants. The study started on 2019-10-01. Estimated completion is 2025-12-02.
What conditions does trial NCT03102125 study?
This clinical trial studies the following conditions: Heart Transplant Failure and Rejection.
What interventions are being tested in trial NCT03102125?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT03102125?
This trial is sponsored by Paul Kim, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03102125 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant Failure and Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
RECRUITING · Phase 2
-
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
ACTIVE NOT RECRUITING
-
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
ACTIVE NOT RECRUITING · NA
-
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
ACTIVE NOT RECRUITING · NA
-
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
- NCT06696352 · 376 participants · NA
Partners4Pain & Wellbeing: A Randomized Trial of Community Supported Complementary and Integrative Health Self-management for Back Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI